版本:
中国

BRIEF-Omeros reports more positive data in OMS721 phase 2 trial in renal diseases

March 30 Omeros Corp

* Omeros reports more positive data in OMS721 phase 2 trial in renal diseases

* Phase 3 program slated for this year

* Consistent with all other OMS721 clinical trials, no significant safety concerns have been observed

* Preparing breakthrough application and phase 3 protocol for discussion with FDA; phase 3 trial in IGAN expected to begin this year

* New data corroborate and expand on trial results reported in Q4 of 2016 Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐